



an Open Access Journal by MDPI

Emerging Issues in COVID and T Cells

Guest Editor:

Dr. Emilia Jaskuła

1. L. Hirsztfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
2. Lower Silesian Oncology, Pulmonology, and Hematology Center, Wrocław, Poland

Deadline for manuscript submissions:

closed (29 February 2024)

Message from the Guest Editor

As variants such as Omicron evolve to avoid antibodies, the role of another part of the immune system, T cells, seems to become more prominent.

In this research topic, we would like to include recent scientific developments on the role of T cells in SARS-CoV-2 infection and immune response post vaccination.

We cordially invite authors to contribute original research articles or reviews focusing on, but not limited to, the following:

- Functional characterization of SARS-CoV-2 T-cell response to infection and vaccination.
- Phenotypic characteristic of T-cell subpopulations during SARS-CoV-2 infection and/or post-vaccination.
- Mechanisms regulating infection/vaccine-induced T-cell longevity.
- Characterization of immune memory induced by SARS-CoV-2 infections and vaccines.
- Cross-talk between T cells and other immune system components in infection or vaccination.
- Factors that influence T-cell responses (immunizing; immunosenescence; malignancy onset; or the influence of associated immunotherapies, drugs, or immunosuppression).
- Role of TCRs and HLA in T-cell response to SARS-CoV-2 infection or vaccines.



mdpi.com/si/115816

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)